Targeting HIV broadly neutralizing antibody precursors with precision in humans.

Featured News
This is an HIV antibody with a yellow core and pink outer shell.

The GW VRU participated in a phase 1 human clinical trial for a recombinant HIV vaccine. This study has promising results and provides proof-of-concept for Env trimer-based GT approaches to activate broadly neutralizing antibody (bnAb) precursors and induce affinity maturation on the path toward mature bnAbs. The structural analyses demonstrate that precise targeting of bnAb precursors with atomic-level accuracy can now be achieved, heralding a new era of vaccine design.

(image from Alamy Stock Photo)

Click here to read the article.
HIV Vaccine

Latest News

Picture of antibodies.
HIV vaccine using mRNA-encoded nanoparticles showed to be safe and well-tolerated
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
Latest Publication:
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below:
Flyer of Featured Presentation by Dr. Nadine Rouphael, Executive Director of the Hope Clinic at the Emory Vaccine Center
NEW Seminar Series: State-of-the-art Topics in Vaccinology
You are invited to attend the first featured presentation in the "State-of-the-Art Topics in Vaccinology" Seminar Series on Tuesday January 28, 2025 at 2 pm. by Dr. Nadine Rouphael, Executive Director of the Hope Clinic at the Emory Vaccine Center.